Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (12016)	12/28/2018 1:27:43 PM
From: bmaz001	Read Replies (2) \| Respond to of 12215

Here are a few catalysts to consider.

To: tuck who wrote (12016)	8/1/2019 4:45:18 PM
From: tuck	1 Recommendation Recommended By scaram(o)uche Read Replies (1) \| Respond to of 12215

VKTX animal tox data in first half 19: not much to add wrt to "success." Clues in old Metabasis studies, perhaps? From today's quarterly PR . . . >> Pre-IND package submitted for VK2809; Initiation of Phase 2b NASH trial planned in 2H19. The company recently submitted a pre-investigational new drug (pre-IND) meeting briefing package to the Food and Drug Administration (FDA) for VK2809 and expects to receive written feedback from the agency in the coming weeks. A new IND is required as the existing IND is filed with the FDA's Division of Metabolic and Endocrinology Products, while most NASH drugs are reviewed in the Division of Gastroenterology and Inborn Errors Products. The company expects to file an IND application for VK2809 and initiate a Phase 2b study in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) in 2H19.<< I would guess animal tox data is in there, but they're damned if they're going to share it with us. As a result, still no position. Cheers, Tuck